NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.

doi:10.1016/j.ejca.2021.09.035

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.

European journal of cancer (Oxford, England : 1990) - 1 Dec 2021

Thielmann Carl M, Chorti Eleftheria, Matull Johanna, Murali Rajmohan, Zaremba Anne, Lodde Georg, Jansen Philipp, Richter Luisa, Kretz Julia, Möller Inga, Sucker Antje, Herbst Rudolf, Terheyden Patrick, Utikal Jochen, Pföhler Claudia, Ulrich Jens, Kreuter Alexander, Mohr Peter, Gutzmer Ralf, Meier Friedegund, Dippel Edgar, Weichenthal Michael, Paschen Annette, Livingstone Elisabeth, Zimmer Lisa, Schadendorf Dirk, Hadaschik Eva, Ugurel Selma, Griewank Klaus G

Abstract excerpt

BACKGROUND: NF1-mutated tumours represent a small subset (10-15%) of melanomas, not sufficiently analysed in large clinical cohorts. This study investigated the largest multicentre collection of NF1-mutated melanomas to date. METHODS: This study analysed a multicentre tumour tissue sample cohort from 266 patients with NF1-mutated melanoma. Targeted next-generation sequencing of the TERT promoter and 29 relevant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Neurofibromin 1

Share to Skin Neoplasms

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 34742158
DOI: 10.1016/j.ejca.2021.09.035
PMCID: PMC9431958

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.PMID 34742158Read ↗

NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.Semantic proximity Read ↗

Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.Semantic proximity Read ↗

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.Semantic proximity Read ↗

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.Semantic proximity Read ↗

Whole-genome landscapes of major melanoma subtypes.Semantic proximity Read ↗

The NF1 gene in tumor syndromes and melanoma.Semantic proximity Read ↗

Targeted Genomic Profiling of Acral MelanomaSemantic proximity Read ↗

Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.Semantic proximity Read ↗

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsSemantic proximity Read ↗

Integrated molecular drivers coordinate biological and clinical states in melanoma.Semantic proximity Read ↗

BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.Semantic proximity Read ↗

Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.